Jameel Ahmed S Mulla

Dr. Jameel Ahmed S Mulla


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
JMJameel Ahmed S Mulla
Jameel Ahmed S Mulla
Mostafa MabroukMostafa Mabrouk
Mostafa Mabrouk
Yahya ChoonaraYahya Choonara
Yahya Choonara
PKPradeep Kumar
Pradeep Kumar
DCDharmesh R. Chejara
Dharmesh R. Chejara
VPViness Pillay
Viness Pillay

1 July 2015 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
Mostafa MabroukMostafa Mabrouk
Mostafa Mabrouk
DCD.R. Chejara
D.R. Chejara
JMJameel Ahmed S Mulla
Jameel Ahmed S Mulla
RBR.V. Badhe
R.V. Badhe
Yahya ChoonaraYahya Choonara
Yahya Choonara
VPViness Pillay
Viness Pillay

1 June 2023 in Saudi Pharmaceutical Journal
Verified
Journal Article
Open access
DMDebarati Maiti
Debarati Maiti
MIMohammed Naseeruddin Inamdar
Mohammed Naseeruddin Inamdar
MAMansour Almuqbil
Mansour Almuqbil
SSSarasija Suresh
Sarasija Suresh
SASyed Mohammed Basheeruddin Asdaq
Syed Mohammed Basheeruddin Asdaq
SRSyed Rabbani
Syed Rabbani
Methotrexate (MTX) is commonly used to manage psoriasis. The drug has erratic absorption characteristics and shows several complications. The present study uses different experimental models to evaluate the solid-lipid nanoparticles of MTX (SLN-MTX) for the anti-psoriatic effect. A prepared SLN-MTX formulation was used and its permeability studies were conducted on Wistar rat abdominal skin. The organ-level distribution of the drug in the formulation was tested in mice and the in-vitro anti-psoriatic activity was determined in CL-177; XB-2 keratinocytes cell lines. The efficacy of SLN-MTX formulation was compared with standard MTX and marketed MTX preparations. The results are analyzed statistically using the student’s t-test. The data suggested that MTX from the formulation was slowly released and completely (80.36%) permeated through the skin. The flux and permeation data were found to be maximum for SLN-MTX compared to marketed and standard preparations. MTX in the formulation was found to be distributed more in the liver (67.5%) and kidney (2.34%). Further, SLN-MTX formulation showed dose-dependent inhibition on the growth of keratinocytes, and the cytotoxic concentration (CTC50) was found to be the least (518 mcg/ml). The findings suggested that MTX in solid-lipid nanoparticles could be a promising formulation for the management of psoriasis since the drug was slowly released, progressively inhibited the growth of keratinocytes, and distributed mostly in organs meant for elimination. More studies in this direction might establish the precise safety and efficacy of SLN-MTX formulation in psoriasis.

12 January 2014 in Medicinal Chemistry Research
Verified
Journal Article
Closed access
PDF file
JMJameel Ahmed S Mulla
Jameel Ahmed S Mulla
MKMohammed Iqbal A. Khazi
Mohammed Iqbal A. Khazi
SPShridhar I. Panchamukhi
Shridhar I. Panchamukhi
YGYoung-Dae Gong
Young-Dae Gong
IKImtiyaz Ahmed M. Khazi
Imtiyaz Ahmed M. Khazi

28 May 2024 in Indian Journal of Pharmaceutical Education and Research
Verified
Journal Article
Open access
PDF file
SCSnehal Shashikant Chakorkar
Snehal Shashikant Chakorkar
JMJameel Ahmed S Mulla
Jameel Ahmed S Mulla
Background Fluorometholone is an anti-inflammatory glucocorticoid. It has been used in various ocular inflammatory as well as infectious conditions. Opting for sustained release in ocular drug delivery is a favorable option for managing ocular diseases. To improve efficacy and to overcome side effects, fluorometholone was encapsulated in cubosomal vesicles. Aim In this study, fluorometholone-loaded cubosomal vesicles were prepared using top-down techniques and applying the QbD approach. The optimized formulation releases the drug in a sustained release manner. Materials and Methods The optimization of cubosomal vesicles was conducted using a 32-CDD. The independent parameter was selected: Concentration of both polymers Glyceryl monooleate (GMO) and Poloxamer 407 (P407), sonication time. The desired property for five important critical attributes of fluorometholone-loaded cubosome vesicles, namely % entrapment efficiency, Cumulative drug release, particle size, polydispersity index and Viscosity. Results and Discussion The optimized formulation suggested by the central composite design was the concentration of GMO and P407; sonication times were 0.36 g, 0.46 g and 8 min, respectively. The optimized formulation exhibited % entrapment efficiency, % Cumulative drug release, particle size, polydispersity index and Viscosity were 82.89%, 88.33%, 137.7 μn, 0.22 and 169.3 m.Pas. The results confirm that implementing a QbD approach in cubosomal design leads to demonstrably improved formulation outcomes. The optimized batch was used for further evaluation like pH and Refractive index, Morphological feature evaluation, Release kinetics study, Test for sterility and stability and in vivo pharmacokinetic study. Conclusion The present work confirms the improved ocular bioavailability of fluorometholone-loaded cubosomes.

1 December 2015 in Materials Letters
Verified
Journal Article
Closed access
Mostafa MabroukMostafa Mabrouk
Mostafa Mabrouk
DBDivya Bijukumar
Divya Bijukumar
JMJameel Ahmed S Mulla
Jameel Ahmed S Mulla
DCDharmesh R. Chejara
Dharmesh R. Chejara
RBRavindra V. Badhe
Ravindra V. Badhe
VPViness Pillay
Viness Pillay